WFH 2018 World Congress

Please register to access the replay*

*Privacy notice

Audio Webcast Replay

Agenda
Welcome
Hemophilia A without inhibitors remains an unmet medical need
HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors
HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments
Q&A
Karl Mahler, Head of Investor Relations
Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab)
Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa
Gallia Levy, MD, Associate Group Medical Director Hematology
Investors
Past IR Events
View more Events

Downloads

Related links